CNTA logo

Centessa Pharmaceuticals (CNTA) Company Overview

Profile

Full Name:

Centessa Pharmaceuticals plc

Sector:

Healthcare

Industry:

Biotechnology

Country:

United Kingdom

IPO:

May 28, 2021

Indexes:

Not included

Description:

Centessa Pharmaceuticals (CNTA) is a biopharmaceutical company focused on developing innovative medicines. They use a unique model to combine multiple drug programs, targeting various diseases. Their goal is to bring new treatments to patients by leveraging advanced science and technology in drug development.

Events Calendar

Earnings

Next earnings date:

Mar 28, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

Mar 28, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Jan 7, 25 TD Cowen
Buy
Nov 15, 24 Guggenheim
Buy
Sep 19, 24 Morgan Stanley
Overweight
Sep 19, 24 B. Riley Securities
Buy
Sep 16, 24 BMO Capital
Outperform
Sep 11, 24 Jefferies
Buy
Sep 11, 24 Guggenheim
Buy
Sep 9, 24 BMO Capital
Outperform
Aug 14, 24 Oppenheimer
Outperform
Jul 18, 24 Oppenheimer
Outperform

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update
CNTA
globenewswire.comNovember 12, 2024

BOSTON and LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients, today reported financial results for the third quarter ended September 30, 2024, and provided a business update.

Wake Up to This Biotech Stock That Still Has Big Potential Upside
Wake Up to This Biotech Stock That Still Has Big Potential Upside
Wake Up to This Biotech Stock That Still Has Big Potential Upside
CNTA
marketbeat.comSeptember 28, 2024

Centessa Pharmaceuticals NASDAQ: CNTA is a biotechnology stock that has nearly doubled its value so far this year, and its run may not be over. Analysts at Morgan Stanley have just massively raised their price target for the company.

Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
CNTA
globenewswire.comSeptember 26, 2024

Late-breaking poster presentation of non-human primate (NHP) data support ORX142 as novel drug candidate for the treatment of excessive daytime sleepiness (EDS) in select neurological, neurodegenerative, and psychiatric disorders

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares
Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares
Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares
CNTA
globenewswire.comSeptember 12, 2024

BOSTON and LONDON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the pricing of an upsized underwritten public offering of 15,254,237 of American Depositary Shares (“ADSs”), each representing one ordinary share, at a price to the public of $14.75 per ADS. The aggregate gross proceeds to Centessa from this offering are expected to be approximately $225 million, before deducting underwriting discounts and commissions and offering expenses payable by Centessa. All ADSs sold in the offering were offered by Centessa. The offering is expected to close on or about September 16, 2024, subject to customary closing conditions. Centessa has also granted the underwriters a 30-day option to purchase up to an additional 2,288,135 ADSs at the public offering price, less underwriting discounts and commissions.

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
CNTA
globenewswire.comSeptember 11, 2024

BOSTON and LONDON, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that it has commenced an underwritten public offering of $150 million of American Depositary Shares (“ADSs”), each representing one ordinary share. All of the ADSs are being offered by Centessa. In addition, Centessa intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of ADSs offered in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024
CNTA
globenewswire.comAugust 13, 2024

BOSTON and LONDON, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today reported financial results and business highlights for the second quarter ended June 30, 2024.

Down -10.98% in 4 Weeks, Here's Why You Should You Buy the Dip in Centessa Pharmaceuticals (CNTA)
Down -10.98% in 4 Weeks, Here's Why You Should You Buy the Dip in Centessa Pharmaceuticals (CNTA)
Down -10.98% in 4 Weeks, Here's Why You Should You Buy the Dip in Centessa Pharmaceuticals (CNTA)
CNTA
zacks.comMay 28, 2024

Centessa Pharmaceuticals (CNTA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

7 Biotech Stocks Ready to Ride the Sector's Resurgence
7 Biotech Stocks Ready to Ride the Sector's Resurgence
7 Biotech Stocks Ready to Ride the Sector's Resurgence
CNTA
InvestorPlaceMarch 18, 2024

Why do you want to consider biotech stocks? Simply, the narrative comes down to numbers and a possible rotation.

Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
CNTA
GlobeNewsWireFebruary 9, 2024

BOSTON & LONDON, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced that data from an additional 52-weeks of continuous treatment from the third year (Part 5) of the ongoing Phase 2a study of SerpinPC for the treatment of hemophilia, will be presented during an oral presentation at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) in Frankfurt, Germany, today, February 9, 2024. The Company previously shared Part 5 results during a poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting. SerpinPC is an investigational subcutaneously administered novel inhibitor of activated protein C (APC) in registrational studies for the treatment for hemophilia B, with or without inhibitors.

Centessa Pharmaceuticals: Clinical Advances And Unique Business Model Highlight Growth Potential
Centessa Pharmaceuticals: Clinical Advances And Unique Business Model Highlight Growth Potential
Centessa Pharmaceuticals: Clinical Advances And Unique Business Model Highlight Growth Potential
CNTA
Seeking AlphaFebruary 5, 2024

Centessa Pharmaceuticals: Clinical Advances And Unique Business Model Highlight Growth Potential

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the ticker symbol for Centessa Pharmaceuticals?
  • Does Centessa Pharmaceuticals pay dividends?
  • What sector is Centessa Pharmaceuticals in?
  • What industry is Centessa Pharmaceuticals in?
  • What country is Centessa Pharmaceuticals based in?
  • When did Centessa Pharmaceuticals go public?
  • Is Centessa Pharmaceuticals in the S&P 500?
  • Is Centessa Pharmaceuticals in the NASDAQ 100?
  • Is Centessa Pharmaceuticals in the Dow Jones?
  • When was Centessa Pharmaceuticals's last earnings report?
  • When does Centessa Pharmaceuticals report earnings?
  • Should I buy Centessa Pharmaceuticals stock now?

What is the ticker symbol for Centessa Pharmaceuticals?

The ticker symbol for Centessa Pharmaceuticals is NASDAQ:CNTA

Does Centessa Pharmaceuticals pay dividends?

No, Centessa Pharmaceuticals does not pay dividends

What sector is Centessa Pharmaceuticals in?

Centessa Pharmaceuticals is in the Healthcare sector

What industry is Centessa Pharmaceuticals in?

Centessa Pharmaceuticals is in the Biotechnology industry

What country is Centessa Pharmaceuticals based in?

Centessa Pharmaceuticals is headquartered in United Kingdom

When did Centessa Pharmaceuticals go public?

Centessa Pharmaceuticals's initial public offering (IPO) was on May 28, 2021

Is Centessa Pharmaceuticals in the S&P 500?

No, Centessa Pharmaceuticals is not included in the S&P 500 index

Is Centessa Pharmaceuticals in the NASDAQ 100?

No, Centessa Pharmaceuticals is not included in the NASDAQ 100 index

Is Centessa Pharmaceuticals in the Dow Jones?

No, Centessa Pharmaceuticals is not included in the Dow Jones index

When was Centessa Pharmaceuticals's last earnings report?

Centessa Pharmaceuticals's most recent earnings report was on Nov 12, 2024

When does Centessa Pharmaceuticals report earnings?

The next expected earnings date for Centessa Pharmaceuticals is Mar 28, 2025

Should I buy Centessa Pharmaceuticals stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions